Trial Profile
Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 06 Apr 2020
Price :
$35
*
At a glance
- Drugs Nitric oxide (Primary)
- Indications COVID 2019 infections; Lung disorders
- Focus Therapeutic Use
- 06 Apr 2020 New trial record
- 01 Apr 2020 According to an Mallinckrodt plc media release, Dr. Chris Miller is the team lead for the study at Vancouver Coastal Health Research Institute.
- 01 Apr 2020 According to an Mallinckrodt plc media release, the companies expect to begin recruiting patients in the coming days.